New hope for kidney transplant patients: experimental drug aims to prevent rejection
Disease control
Not yet recruiting
This study tests a new medicine called siplizumab to see if it can help prevent kidney transplant rejection better than a standard treatment. About 120 adults getting a kidney transplant will receive either siplizumab or the usual anti-rejection drug, along with standard anti-rej…
Phase: PHASE2 • Sponsor: Nefro Avillion Clinical Development, LLC • Aim: Disease control
Last updated May 04, 2026 16:22 UTC